{"schema_version":"1","generated_at":"2026-10-28T19:48:34.026Z","data_as_of":null,"url":"https://www.findmykol.com/kol/omar-nadeem","json_url":"https://www.findmykol.com/kol/omar-nadeem/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"omar-nadeem","name":"Omar Nadeem","credential":"MD","specialty":"Hematology","specialty_raw":"Hematology","therapeutic_area":"Hematology","therapeutic_areas":["Hematology"],"institution":"Harvard University","institution_url":"https://www.findmykol.com/institution/harvard-university","city":"Boston","state":"MA","region":{"label":"Northeast","url":"https://www.findmykol.com/region/northeast"}},"identifiers":{"npi":"1215170691","orcid":"0000-0002-4124-4277","openalex":"A5052163068"},"summary":"Omar Nadeem is a Hematology physician affiliated with Harvard University. OpenAlex indexes 286 publications with 2,603 citations (h-index 24); ClinicalTrials.gov lists 4 registered studies matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Hematology"]},"scholarship":{"works_count":286,"cited_by_count":2603,"h_index":24,"latest_activity_year":2025,"source":"works"},"trials":{"count":4,"shown":3,"withheld":1,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT06518551","title":"Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM","phase":"PHASE1/PHASE2","status":"RECRUITING","role":"Overall official","sponsor":"Omar Nadeem, MD","source_url":"https://clinicaltrials.gov/study/NCT06518551","trial_url":"https://www.findmykol.com/trial/NCT06518551"},{"nct":"NCT04850846","title":"Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","role":"Overall official","sponsor":"Dana-Farber Cancer Institute","source_url":"https://clinicaltrials.gov/study/NCT04850846","trial_url":"https://www.findmykol.com/trial/NCT04850846"},{"nct":"NCT04775550","title":"DARA RVD For High Risk SMM","phase":"PHASE2","status":"ACTIVE_NOT_RECRUITING","role":"Overall official","sponsor":"Omar Nadeem, MD","source_url":"https://clinicaltrials.gov/study/NCT04775550","trial_url":"https://www.findmykol.com/trial/NCT04775550"}],"source":"trials"},"payments":{"company_count":16,"program_years":{"first":2021,"last":null},"rows_total":30,"shown":3,"withheld":27,"rows":[{"payer":"Janssen Research & Development, LLC","program_year":2025,"amount_usd":27879.84,"payment_count":2,"source_url":"https://openpaymentsdata.cms.gov/search?query=1215170691"},{"payer":"Kite Pharma, Inc.","program_year":2025,"amount_usd":16810.76,"payment_count":11,"source_url":"https://openpaymentsdata.cms.gov/search?query=1215170691"},{"payer":"E.R. Squibb & Sons, L.L.C.","program_year":2025,"amount_usd":6822.24,"payment_count":3,"source_url":"https://openpaymentsdata.cms.gov/search?query=1215170691"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1215170691","source":"payments"},"prescribing":{"data_year":2024,"areas_total":2,"areas_shown":2,"areas":[{"area":"Cancer & immunology","share_pct":75,"classes_total":1,"classes":[{"class":"Thalidomide Analog","setting":"prescribed","share_pct":75,"drugs":[{"name":"Revlimid","share_pct":100}],"max_beneficiaries":24}]},{"area":"Dermatology","share_pct":25,"classes_total":1,"classes":[{"class":"Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor","setting":"prescribed","share_pct":25,"drugs":[{"name":"Acyclovir","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"facility","data_year":2024,"office_pct":10.2,"facility_pct":89.8},"source":"medicare"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma","year":2025,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco-24-01730","status":"verified"},{"title":"Sequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapy","year":2025,"journal":"Blood","source_url":"https://doi.org/10.1182/blood.2025029773","status":"verified"},{"title":"Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium","year":2025,"journal":"Blood Cancer Discovery","source_url":"https://doi.org/10.1158/2643-3230.bcd-24-0354","status":"verified"},{"title":"Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial","year":2025,"journal":"Nature Communications","source_url":"https://doi.org/10.1038/s41467-024-55308-5","status":"verified"},{"title":"Bridging intensity is associated with impaired hematopoietic recovery after BCMA CAR-T therapy for multiple myeloma","year":2025,"journal":"Blood Advances","source_url":"https://doi.org/10.1182/bloodadvances.2024015732","status":"verified"}],"source":"works"},"contact":{"address_1":"450 BROOKLINE AVE","city":"Boston","state":"MA","zip":"02215","phone":"617-632-6140","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1215170691","source":"identity"},"similar":[{"name":"Felipe Fregni","slug":"felipe-fregni","institution":"Harvard University","specialty":"Neurology","url":"https://www.findmykol.com/kol/felipe-fregni","json_url":"https://www.findmykol.com/kol/felipe-fregni/profile.json"},{"name":"Joseph Antin","slug":"joseph-antin","institution":"Harvard University","specialty":"Hematology","url":"https://www.findmykol.com/kol/joseph-antin","json_url":"https://www.findmykol.com/kol/joseph-antin/profile.json"},{"name":"Sarah Fortune","slug":"sarah-fortune","institution":"Harvard University","specialty":"Infectious Disease","url":"https://www.findmykol.com/kol/sarah-fortune","json_url":"https://www.findmykol.com/kol/sarah-fortune/profile.json"},{"name":"Ethan Lerner","slug":"ethan-lerner","institution":"Harvard University","specialty":"Dermatology","url":"https://www.findmykol.com/kol/ethan-lerner","json_url":"https://www.findmykol.com/kol/ethan-lerner/profile.json"},{"name":"Scott Kaufmann","slug":"scott-kaufmann","institution":"Mayo Clinic College of Medicine","specialty":"Hematology","url":"https://www.findmykol.com/kol/scott-kaufmann","json_url":"https://www.findmykol.com/kol/scott-kaufmann/profile.json"},{"name":"Jeffrey Miller","slug":"jeffrey-miller","institution":"University of Minnesota Medical School","specialty":"Hematology","url":"https://www.findmykol.com/kol/jeffrey-miller","json_url":"https://www.findmykol.com/kol/jeffrey-miller/profile.json"},{"name":"Ruben Mesa","slug":"ruben-mesa","institution":"Atrium Health Wake Forest Baptist Comprehensive Cancer Center","specialty":"Hematology","url":"https://www.findmykol.com/kol/ruben-mesa","json_url":"https://www.findmykol.com/kol/ruben-mesa/profile.json"}],"coverage":{"note":"A basic record from the physician directory. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"trials":1,"payments":27,"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2018-06-06","collected_at":"2026-10-27T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024}},"methodology_url":"https://www.findmykol.com/about#methodology"}